Literature DB >> 21298382

Histopathologic evaluation of patent ductus arteriosus stents after hybrid stage I palliation.

Matthew J Egan1, Aaron J Trask1, Peter B Baker2, Jonathan Lawrence1, Elena Ladich3, Renu Virmani3, Sharon L Hill1, John P Cheatham1, Mark Galantowicz1, Pamela A Lucchesi1, John P Kovalchin1.   

Abstract

The aim of this study was to determine the histopathology of patent ductus arteriosus (PDA) in-stent stenosis after hybrid stage I palliation. The hybrid approach to palliation of hypoplastic left heart syndrome can be complicated by the development of in-stent stenosis of the PDA. This may obstruct retrograde aortic arch flow, decrease systemic circulation, and lead to interstage interventional procedures. Stented PDA samples removed from eight patients undergoing comprehensive stage II repair were examined by way of radiography and histochemistry (hematoxylin and eosin, Movat pentachrome, α-smooth muscle actin, and proliferating cell nuclear antigen). A retrospective chart review of the patients was also performed. PDA stents were in place in the PDA for a mean period of 169 ± 28 days in patients who had a mean age of 176 ± 30 days at the time of stent removal. Stent deployment caused chronic inflammation, caused fibrin deposition, and induced vascular smooth muscle-cell (VSMC) proliferation in the area immediately surrounding the stent struts. The neointimal region was composed largely of smooth muscle cells that appeared to be fully differentiated by the lack of PCNA staining. Neointimal thickening occurs in the PDA after stent placement for hybrid palliation of HLHS and is the result of inflammation, extracellular matrix deposition, and smooth muscle-cell proliferation in the peristrut region. This finding suggests that proliferating VSMCs in the peristrut region may provide the impetus for inward neointimal formation and therefore the manifestation of in-stent stenosis.

Entities:  

Mesh:

Year:  2011        PMID: 21298382      PMCID: PMC3822434          DOI: 10.1007/s00246-010-9870-y

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  17 in total

Review 1.  Pathology of in-stent restenosis.

Authors:  R Virmani; A Farb
Journal:  Curr Opin Lipidol       Date:  1999-12       Impact factor: 4.776

Review 2.  The porcine coronary model of in-stent restenosis: current status in the era of drug-eluting stents.

Authors:  Harry C Lowe; Robert S Schwartz; Briain D Mac Neill; Ik-Kyung Jang; Motoya Hayase; Campbell Rogers; Stephen N Oesterle
Journal:  Catheter Cardiovasc Interv       Date:  2003-12       Impact factor: 2.692

3.  Successful placement and re-expansion of a new balloon expandable stent to maintain patency of the ductus arteriosus in a newborn animal model.

Authors:  Z M Hijazi; M J Aronovitz; G R Marx; D R Fulton
Journal:  J Invasive Cardiol       Date:  1993 Nov-Dec       Impact factor: 2.022

4.  T-type Ca2+ channels promote oxygenation-induced closure of the rat ductus arteriosus not only by vasoconstriction but also by neointima formation.

Authors:  Toru Akaike; Mei-Hua Jin; Utako Yokoyama; Hiroko Izumi-Nakaseko; Qibin Jiao; Shiho Iwasaki; Mari Iwamoto; Shigeru Nishimaki; Motohiko Sato; Shumpei Yokota; Yoshinori Kamiya; Satomi Adachi-Akahane; Yoshihiro Ishikawa; Susumu Minamisawa
Journal:  J Biol Chem       Date:  2009-06-30       Impact factor: 5.157

5.  Medium-term results of experimental stent implantation into the ductus arteriosus.

Authors:  E Rosenthal; S A Qureshi; A H Tabatabaie; D Persaud; A P Kakadekar; E J Baker; M Tynan
Journal:  Am Heart J       Date:  1996-09       Impact factor: 4.749

6.  The retrograde aortic arch in the hybrid approach to hypoplastic left heart syndrome.

Authors:  Serban C Stoica; Alistair B Philips; Matthew Egan; Roberta Rodeman; Joanne Chisolm; Sharon Hill; John P Cheatham; Mark E Galantowicz
Journal:  Ann Thorac Surg       Date:  2009-12       Impact factor: 4.330

7.  Initial results and medium-term follow-up of stent implantation of patent ductus arteriosus in duct-dependent pulmonary circulation.

Authors:  Mazeni Alwi; K K Choo; Haifa Abdul Latiff; Geetha Kandavello; Hasri Samion; M D Mulyadi
Journal:  J Am Coll Cardiol       Date:  2004-07-21       Impact factor: 24.094

8.  Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model.

Authors:  A J Carter; J R Laird; A Farb; W Kufs; D C Wortham; R Virmani
Journal:  J Am Coll Cardiol       Date:  1994-11-01       Impact factor: 24.094

9.  A novel method to maintain ductus arteriosus patency.

Authors:  J Y Coe; P M Olley
Journal:  J Am Coll Cardiol       Date:  1991-09       Impact factor: 24.094

10.  Rapamycin-eluting stents in the arterial duct: experimental observations in the pig model.

Authors:  Kyong-Jin Lee; Aleksander Hinek; Rajiv R Chaturvedi; Claudia L Almeida; Osami Honjo; Gideon Koren; Leland N Benson
Journal:  Circulation       Date:  2009-04-06       Impact factor: 29.690

View more
  3 in total

1.  Potential Molecular Mechanism of Retrograde Aortic Arch Stenosis in the Hybrid Approach to Hypoplastic Left Heart Syndrome.

Authors:  Narutoshi Hibino; Mary J Cismowski; Brenda Lilly; Patrick I McConnell; Toshiharu Shinoka; John P Cheatham; Pamela A Lucchesi; Mark E Galantowicz; Aaron J Trask
Journal:  Ann Thorac Surg       Date:  2015-07-07       Impact factor: 4.330

2.  Predictors of ductus arteriosus in-stent stenosis in the hybrid approach to hypoplastic left heart syndrome.

Authors:  Holly A Nadorlik; Matthew J Egan; Sharon L Hill; John P Cheatham; Mark Galantowicz; John P Kovalchin
Journal:  Pediatr Cardiol       Date:  2012-10-13       Impact factor: 1.655

3.  Proximal ductus arteriosus stenosis after the hybrid stage I procedure in a newborn with hypoplastic left heart syndrome.

Authors:  Maciej Chojnicki; Ireneusz Haponiuk; Mariusz Steffens; Radoslaw Jaworski; Aneta Szofer-Sendrowska; Jacek Juscinski; Ewelina Kwasniak
Journal:  Postepy Kardiol Interwencyjnej       Date:  2013-06-17       Impact factor: 1.426

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.